Table 4 Relationship between preoperative absolute serum CA125 levels and survival in ovarian cancer
From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
|---|---|---|---|---|---|---|---|
Osman N, 2008, Limerick [53] | Jan 2001 to Dec 2005 | Retrospective study | 75 | ≤ 500 u/ml, > 500 u/ml | NA, 0.85 | The preoperative CA125 level did not correlate significantly with stage, tumor grade or survival | Age, histology, FIGO stage, grade |
Petri A, 2006, Denmark [54] | Dec 1994 to May 1999 | Retrospective study | 118 | < 65 U/mL, ≥ 65 U/mL | 3.4 (1.2--9.6), 0.01 | Patients with stage I EOC and preoperative serum CA125 levels < 65 U/mL had a significantly longer survival compared to those with serum CA125 ≥ 65 U/mL | Age, histology FIGO substage, grade, chemotherapy |
Cooper BC, 2002, USA [55] | 1990 to 1996 | Retrospective study | 142 | < 160, 160--399, 400--924, 925--2399, 2400 U/mL | GI-Reference, GII-2, GIII-1.5, GIV-4, GV-2, 0.03 (for trend) | There was a significant association between CA125 levels and disease-specific survival | Age, histology FIGO stage, grade, ascites, and optimal cytoreduction |
Buller R, 1996, USA [56] | 1987 to 1982 | Retrospective study | 126 | ≤ 500 U/ml, > 500 U/ml, ≤ 3000 U/ml, > 3000 U/ml | I-HR-NA, 0.48 II-HR-NA, 0.65 | Preoperative CA125 levels did not predict survival advantage over a range of cut points (400 to 3000 U/ml) | Age, histology, FIGO stage, tumor grade, residual disease, time to initial chemotherapy |
Geisler JP, 1996, USA [57] | NA | Consecutive case series | 82 | NA | NA, 0.047 | In epithelial ovarian carcinoma, high preoperative serum levels of CA125 predict decreased length of survival | Histology FIGO substage, grade |
Gadducci A, 1995, Italy [40] | 1986 to 1992 | Multicentric retrospective study | 225 | ≥ 500 U/ml, < 500 U/ml | NA | Serum CA125 half-life during early chemotherapy was an independent prognostic factor for survival | FIGO stage, tumor grade, size of residual disease & serum CA125 half life |
Nagele F, 1995, Austria [58] | Jan 1984 to June 1993 | Retrospective study | 201 | < 65 U/mL, ≥ 65 U/mL | Uni-7.45 (2.83-19.65), < 0.001 Multi-6.37 (2.39-16.97), < 0.001 | Preoperative CA125 was the most powerful prognostic factor for survival | Age, FIGO substage, grade, |
Makar AP, 1992, Norway [59] | 1983 to 1990 | Prospective study | 200 | ≤ 150 U/ml, > 150 U/ml | NA, 0.035 | Preoperative CA125 did not appear to be of any prognostic value in epithelial ovarian cancer | NA |
Sevelda P, 1989, Austria [60] | NA | Prospective study | 163 | ≥ 35 U/ml, < 35 U/ml | NA, 0.13 | Preoperative CA125 was not a predictor of survival | Histologic grade, FOGO stage, residual tumor |
Moebus V, 1988, Germany [61] | NA | Convenience sample | 202 | ≥ 65 U/ml, < 65 U/ml | NA, 0.005 | Significantly longer survival was noted for patients with preoperative values below 65 U/ml than for those with values above 65 U/ml | NA |
Cruickshank D, 1987, Aberdeen [62] | NA | Prospective study | 52 | ≥ 35 U/ml, < 35 U/ml | NA | No correlation was found between CA125 concentration and survival | NA |